In the assessment of 12-month price targets, analysts unveil insights for Globus Medical, presenting an average target of $90.4, a high estimate of $103.00, and a low estimate of $80.00. This current ...

Truist lowered the firm’s price target on Globus Medical (GMED) to $80 from $82 and keeps a Hold rating on the shares as part of a broad ...

JMP Securities analyst David Turkaly reiterated a Hold rating on Globus Medical (GMED – Research Report) today. The company’s shares opened ...

GMED recently completed its previously disclosed acquisition of Nevro Corp., a global medical device company that delivers ...

Globus Medial completed its acquisition of Nevero, a spinal cord stimulator company, according to an April 3 news release.

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.

Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its ...

Globus Medical GMED has outperformed the market over the past 10 years by 1.08% on an annualized basis producing an average annual return of 11.62%. Currently, Globus Medical has a market ...

Globus Medical, Inc. (NYSE:GMED – Get Free Report) has earned an average recommendation of “Moderate Buy” from the twelve ...

NYSE GMED opened at $76.65 on Wednesday. The firm has a market capitalization of $10.54 billion, a price-to-earnings ratio of 102.20, a PEG ratio of 1.61 and a beta of 1.19. Globus Medical, Inc ...